Breast cancer

February 18, 2022

Pembrolizumab in treatment of triple-negative breast cance

Pembrolizumab in combination with chemotherapy is already FDA-approved for the treatment of patients with triple-negative breast cancer – in the setting of early or metastatic diseases. […]
February 18, 2022

Neoadjuvant pembrolizumab plus chemotherapy improves event free survival in early TNBC.

Previous data showed that the addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer (TNBC) having […]
June 9, 2021

Esmo Breast Cancer 2021: analysis of two important studies presented during the congress

Clinical Oncologist at Grupo Oncoclínicas discusses phase II DESTINY-Breast01 study and meta-analysis that included four randomized clinical trials involving patients with triple-negative breast cancer    The ESMO Breast Cancer 2021 event, held […]
May 24, 2021

Association of RAD51 with homologous recombination deficiency (HRD) in triple-negative breast cancer (TNBC): Analysis of the GeparSixto trial

Currently available genetic tests analyzing homologous recombination deficiency (HRD) have limited predictive value    During the ESMO Breast Cancer 2021 Congress, in virtual format, a retrospective […]
May 21, 2021

Immunomodulatory effect of denosumab in early breast cancer

Most breast cancers exhibit low T–lymphocyte infiltration and do not respond satisfactorily to immune correceptor inhibitors, leading to the need for new therapeutic strategies that act on anti-tumor immune […]
May 20, 2021

Meta-analysis assesses the efficacy of adding immunotherapy to neoadjuvant chemotherapy in triple-negative breast cancer

Presented during ESMO Breast Cancer 2021, meta-analysis approaches immune checkpoint inhibitors (ICIs), which have shown promising antitumor activities in several malignancies   ESMO Breast Cancer 2021 starts today in virtual format, a […]
April 19, 2021

Selective androgen receptor degraders may provide a future therapeutic option for women with LAR subtype triple-negative breast cancer

Triple-negative breast cancer is an aggressive tumor with lower overall survival compared to other types of breast malignancies. Of the 6 molecularly classified TNBC subtypes, about 10 to […]
March 31, 2021

Molecular signature panel for DCIS predicts risk of local recurrence and benefit of radiotherapy after breast conservative surgery.

Radiotherapy after breast-conserving surgery for the treatment of ductal carcinoma in situ (DCIS) reduces the risk of ipsilateral breast events without changing survival   Between March 18th and 19th, SSO 2021 (International Conference […]
July 15, 2020

Combination of abemaciclib and adjuvant hormone therapy increases invasive disease-free survival in high-risk early breast cancer RH + HER2-

New therapeutic option for patients with high-risk HR-positive, HER2-negative breast cancer Abemaciclib in combination with standard adjuvant endocrine therapy (ET) achieved its primary objective in the […]